Table 1 Clinical and demographic characteristics of the patient cohort. ADC: antibody-drug conjugate; BC: bladder cancer; CKI: checkpoint-inhibitor; N: number of patients; UTUC upper tract urothelial carcinoma
Variable | N = 30 |
|---|---|
Age (median (range)) | 68 (51–83 years) |
Gender | Â |
 Female | 4 (13.3%) |
 Male | 26 (86.7%) |
Therapeutic modality | Â |
 CKI | 15 (50%) |
 Platin-based chemotherapy | 13 (43.3%) |
 ADC | 2 (6.7%) |
Prior therapy lines | Â |
 0 | 15 (50%) |
 1 | 13 (43.3%) |
 2 | 2 (6.7%) |
Entity | Â |
 BC | 20 (66.6%) |
 UTUC | 10 (33.3%) |
ECOG | Â |
 0 | 22 (73.3%) |
 1 | 8 (26.7%) |
Undergone previous surgery | Â |
 Yes | 16 (53.3%) |
 No | 14 (46.7%) |
Immigration Background | Â |
 Yes | 7 (23.33%) |
 No | 23 (76.66%) |